國立虎尾科技大學 |

Development of Biopharmaceutical Drug-Device Products

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Development of Biopharmaceutical Drug-Device Products/ edited by Feroz Jameel, John W. Skoug, Robert R. Nesbitt.
其他作者:	Jameel, Feroz.
面頁冊數:	XVIII, 893 p. 302 illus., 256 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Pharmaceutical technology. -
電子資源:	https://doi.org/10.1007/978-3-030-31415-6
ISBN:	9783030314156

Development of Biopharmaceutical Drug-Device Products
Development of Biopharmaceutical Drug-Device Products[electronic resource] /edited by Feroz Jameel, John W. Skoug, Robert R. Nesbitt. - 1st ed. 2020. - XVIII, 893 p. 302 illus., 256 illus. in color.online resource. - AAPS Advances in the Pharmaceutical Sciences Series,352210-7371 ;. - AAPS Advances in the Pharmaceutical Sciences Series,20.

Foreword -- Preface -- Introduction -- Section I Background of Structure and Function of Engineered Antibiodies -- Monoclonal Antibodies -- Antibody Drug Conjugates (ADCs), DVDs, BiTES (Bispecfic T Cell Engagers) -- Section II Early Stage Analytical, Molecular Assessment and Formulation. -- Leveraging the Multi-Attribute Method (MAM) to Improve Biotherapeutic Characterization -- Addressing Product Heterogenetity in ADC Biotherapeutics: Case Studies -- Cutting-Edge Analytical and Structural Methods for Characterization of ADCs.Cutting edge LC and CE-MS Methods for mABs, ACDs, and Bispecfic Antibodies -- Incorporation of Developability, Manufacturability in Therapeutic Antibody Discovery -- Analytical Characterization of Biologics for Candidate Selection and Optimization: Strategies and Case Studies -- Developability Assessment of Bispecific Antibodies: Analytical Platform and Stability Studies -- Method Development and Qualification and Molecular Assessment - Screening for Drug-like properties of DVDs/ADCs -- Solubility and Early Assessment of Stability for Protein Therapeutics (In general and with specific case studies with modalities Duobody) -- Screening Antibody Candidates (mAbs) for Manufacturability, Stability, and Deliverability -- Practical Considerations in Screening Excipients for Protein Drugs -- Highly-Automated Procedures for the Assessment of Protein Formulations -- Formulation Design for Biologics in the Age of Lab Automation and Biological Performance Screening -- Pushing Formulation Development into Discovery through Antibody Design and High-Throughput Screening -- An Empirical Phase Diagram/ High Throughput Screening Approach to the Characterization and Formulation of Biopharmaceuticals -- Development of a combination drug product for high protein concentration mAbs: Preformulation, formulation and device – A case study with delivery system -- Formulation and Process development of ADC Drug Products -A Case Study -- Formulation and Device Development Strategies for Fusion Protein, A case study -- Development of a combination drug product for BITEs: Pre-formulation, Analytics, formulation and device – A case study -- Challenges in the Development of Pre-filled Syringes with Device for Biologics from a Formulation and device Points of View -- Section III Process Development -- Scale Down Models for Robust Biologics Drug Product Development -- Engineered antibodies —Understanding Intricacies of Formulation and Freeze Thaw Process -- Development and Scale-up of a Commercial Filtration Process -- Filling of High-Concentration Monoclonal Antibody Formulations: Investigating Underlying Mechanisms Impacting Precision of Low Volume Fill by Peristaltic Pump -- Development and Optimization of Freeze drying Process for Engineered antibodies – Case studies -- Section IV Drug Delivery and Device Development -- Considerations for developing a Biologic in a PFS -- Early Device and Container Closure System Evaluation – A case study for Cartridge -- Prefilled Syringe Technologies for Improving Drug Stability and Reliable Plunger Performance for Auto-Injectors Applications -- Global Market Trends for Advanced Combination Products –How Innovations can Contribute to Better Patient Outcomes -- Patient Centricity and System Integration as New Drivers of Biologic Drug Product Design Strategy -- Drug Delivery and Device Development,. A case study -- Development of a Combination Product : A Case Study -- Development Activities Associated with a One-Way Label Reference for a Device for Clinical Use -- Infusion set compatibility and drug delivery challenges of high potency ADCs -- Glossary -- Index. .

The biotechnology/biopharmaceutical sector has tremendously grown which led to the invention of engineered antibodies such as Antibody Drug Conjugates (ADCs), Bispecific T-cell engager (BITES), Dual Variable Domain (DVD) antibodies, and fusion proteins that are currently being used as therapeutic agents for immunology, oncology and other disease conditions. Regulatory agencies have raised the bar for the development and manufacture of antibody-based products, expecting to see the use of Quality by Design (QbD) elements demonstrating an in-depth understanding of product and process based on sound science. Drug delivery systems have become an increasingly important part of the therapy and most biopharmaceuticals for self-administration are being marketed as combination products. A survey of the market indicates that there is a strong need for a new book that will provide “one stop shopping” for the latest information and knowledge of the scientific and engineering advances made over the last few years in the area of biopharmaceutical product development. The new book entitled Development of Biopharmaceutical Drug Device Products is a reference text for scientists and engineers in the biopharmaceutical industry, academia or regulatory agencies. With insightful chapters from experts in the field, this new book reviews first principles, covers recent technological advancements and provides case studies and regulatory strategies relating to the development and manufacture of antibody-based products. It covers topics such as the importance of early preformulation studies during drug discovery to influence molecular selection for development, formulation strategies for new modalities, and the analytical techniques used to characterize them. It also addresses important considerations for later stage development such as the development of robust formulations and processes, including process engineering and modeling of manufacturing unit operations, the design of analytical comparability studies, and characterization of primary containers (pre-filled syringes and vials). Finally, the latter half of the book reviews key considerations to ensure the development and approval of a patient-centered delivery system design. This involves the evolving regulatory framework with perspectives from both the US and EU industry experts, the role of international standards, design control/risk management, human factors and its importance in the product development and regulatory approval process, as well as review of the risk-based approach to bridging between devices used in clinical trials and the to-be-marketed device. Finally, case studies are provided throughout. The typical readership would have biology and/or engineering degrees and would include researchers, scientific leaders, industry specialists and technology developers working in the biopharmaceutical field. .

ISBN: 9783030314156

Standard No.: 10.1007/978-3-030-31415-6doiSubjects--Topical Terms:

557391
Pharmaceutical technology.

LC Class. No.: RS380

Dewey Class. No.: 615.19

Development of Biopharmaceutical Drug-Device Products
LDR:08090nam a22004215i 4500 001 1024632
003 DE-He213
005 20200701052251.0
007 cr nn 008mamaa
008 210318s2020 gw | s |||| 0|eng d
020 $a 9783030314156 $9 978-3-030-31415-6
024 7 $a 10.1007/978-3-030-31415-6 $2 doi
035 $a 978-3-030-31415-6
050 4 $a RS380
050 4 $a RS190-210
072 7 $a TDCW $2 bicssc
072 7 $a MED072000 $2 bisacsh
072 7 $a TDC $2 thema
082 0 4 $a 615.19 $2 23
245 1 0 $a Development of Biopharmaceutical Drug-Device Products $h [electronic resource] / $c edited by Feroz Jameel, John W. Skoug, Robert R. Nesbitt.
250 $a 1st ed. 2020.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2020.
300 $a XVIII, 893 p. 302 illus., 256 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a AAPS Advances in the Pharmaceutical Sciences Series, $x 2210-7371 ; $v 35
505 0 $a Foreword -- Preface -- Introduction -- Section I Background of Structure and Function of Engineered Antibiodies -- Monoclonal Antibodies -- Antibody Drug Conjugates (ADCs), DVDs, BiTES (Bispecfic T Cell Engagers) -- Section II Early Stage Analytical, Molecular Assessment and Formulation. -- Leveraging the Multi-Attribute Method (MAM) to Improve Biotherapeutic Characterization -- Addressing Product Heterogenetity in ADC Biotherapeutics: Case Studies -- Cutting-Edge Analytical and Structural Methods for Characterization of ADCs.Cutting edge LC and CE-MS Methods for mABs, ACDs, and Bispecfic Antibodies -- Incorporation of Developability, Manufacturability in Therapeutic Antibody Discovery -- Analytical Characterization of Biologics for Candidate Selection and Optimization: Strategies and Case Studies -- Developability Assessment of Bispecific Antibodies: Analytical Platform and Stability Studies -- Method Development and Qualification and Molecular Assessment - Screening for Drug-like properties of DVDs/ADCs -- Solubility and Early Assessment of Stability for Protein Therapeutics (In general and with specific case studies with modalities Duobody) -- Screening Antibody Candidates (mAbs) for Manufacturability, Stability, and Deliverability -- Practical Considerations in Screening Excipients for Protein Drugs -- Highly-Automated Procedures for the Assessment of Protein Formulations -- Formulation Design for Biologics in the Age of Lab Automation and Biological Performance Screening -- Pushing Formulation Development into Discovery through Antibody Design and High-Throughput Screening -- An Empirical Phase Diagram/ High Throughput Screening Approach to the Characterization and Formulation of Biopharmaceuticals -- Development of a combination drug product for high protein concentration mAbs: Preformulation, formulation and device – A case study with delivery system -- Formulation and Process development of ADC Drug Products -A Case Study -- Formulation and Device Development Strategies for Fusion Protein, A case study -- Development of a combination drug product for BITEs: Pre-formulation, Analytics, formulation and device – A case study -- Challenges in the Development of Pre-filled Syringes with Device for Biologics from a Formulation and device Points of View -- Section III Process Development -- Scale Down Models for Robust Biologics Drug Product Development -- Engineered antibodies —Understanding Intricacies of Formulation and Freeze Thaw Process -- Development and Scale-up of a Commercial Filtration Process -- Filling of High-Concentration Monoclonal Antibody Formulations: Investigating Underlying Mechanisms Impacting Precision of Low Volume Fill by Peristaltic Pump -- Development and Optimization of Freeze drying Process for Engineered antibodies – Case studies -- Section IV Drug Delivery and Device Development -- Considerations for developing a Biologic in a PFS -- Early Device and Container Closure System Evaluation – A case study for Cartridge -- Prefilled Syringe Technologies for Improving Drug Stability and Reliable Plunger Performance for Auto-Injectors Applications -- Global Market Trends for Advanced Combination Products –How Innovations can Contribute to Better Patient Outcomes -- Patient Centricity and System Integration as New Drivers of Biologic Drug Product Design Strategy -- Drug Delivery and Device Development,. A case study -- Development of a Combination Product : A Case Study -- Development Activities Associated with a One-Way Label Reference for a Device for Clinical Use -- Infusion set compatibility and drug delivery challenges of high potency ADCs -- Glossary -- Index. .
520 $a The biotechnology/biopharmaceutical sector has tremendously grown which led to the invention of engineered antibodies such as Antibody Drug Conjugates (ADCs), Bispecific T-cell engager (BITES), Dual Variable Domain (DVD) antibodies, and fusion proteins that are currently being used as therapeutic agents for immunology, oncology and other disease conditions. Regulatory agencies have raised the bar for the development and manufacture of antibody-based products, expecting to see the use of Quality by Design (QbD) elements demonstrating an in-depth understanding of product and process based on sound science. Drug delivery systems have become an increasingly important part of the therapy and most biopharmaceuticals for self-administration are being marketed as combination products. A survey of the market indicates that there is a strong need for a new book that will provide “one stop shopping” for the latest information and knowledge of the scientific and engineering advances made over the last few years in the area of biopharmaceutical product development. The new book entitled Development of Biopharmaceutical Drug Device Products is a reference text for scientists and engineers in the biopharmaceutical industry, academia or regulatory agencies. With insightful chapters from experts in the field, this new book reviews first principles, covers recent technological advancements and provides case studies and regulatory strategies relating to the development and manufacture of antibody-based products. It covers topics such as the importance of early preformulation studies during drug discovery to influence molecular selection for development, formulation strategies for new modalities, and the analytical techniques used to characterize them. It also addresses important considerations for later stage development such as the development of robust formulations and processes, including process engineering and modeling of manufacturing unit operations, the design of analytical comparability studies, and characterization of primary containers (pre-filled syringes and vials). Finally, the latter half of the book reviews key considerations to ensure the development and approval of a patient-centered delivery system design. This involves the evolving regulatory framework with perspectives from both the US and EU industry experts, the role of international standards, design control/risk management, human factors and its importance in the product development and regulatory approval process, as well as review of the risk-based approach to bridging between devices used in clinical trials and the to-be-marketed device. Finally, case studies are provided throughout. The typical readership would have biology and/or engineering degrees and would include researchers, scientific leaders, industry specialists and technology developers working in the biopharmaceutical field. .
650 0 $a Pharmaceutical technology. $3 557391
650 0 $a Pharmacy. $3 582411
650 1 4 $a Pharmaceutical Sciences/Technology. $3 768561
700 1 $a Jameel, Feroz. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1265986
700 1 $a Skoug, John W. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1320816
700 1 $a Nesbitt, Robert R. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1320817
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030314149
776 0 8 $i Printed edition: $z 9783030314163
776 0 8 $i Printed edition: $z 9783030314170
830 0 $a AAPS Advances in the Pharmaceutical Sciences Series, $x 2210-7371 ; $v 20 $3 1255084
856 4 0 $u https://doi.org/10.1007/978-3-030-31415-6
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)